EN3835 for the Treatment of Edematous Fibrosclerotic Panniculopathy (Commonly Known as Cellulite)

Trial Profile

EN3835 for the Treatment of Edematous Fibrosclerotic Panniculopathy (Commonly Known as Cellulite)

Completed
Phase of Trial: Phase II

Latest Information Update: 09 May 2017

At a glance

  • Drugs Collagenase clostridium histolyticum (Primary)
  • Indications Cellulite
  • Focus Therapeutic Use
  • Sponsors Auxilium Pharmaceuticals; Endo Pharmaceuticals
  • Most Recent Events

    • 15 Mar 2017 According to a BioSpecifics Technologies Corporation media release, full data expected in the second half of 2017.
    • 17 Nov 2016 Results published in the Endo International Media Release.
    • 17 Nov 2016 According to a BioSpecifics Technologies Corporation media release, status changed from active, no longer recruiting to completed.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top